Literature DB >> 11862089

Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis.

Ekaterini T Tsilou1, Benjamin I Rubin, George F Reed, Fumino Iwata, William Gahl, Muriel I Kaiser-Kupfer.   

Abstract

PURPOSE: As a result of successful renal transplantation, patients with nephropathic cystinosis are now living into adulthood. As these patients age, anterior segment ocular complications, other than deposition of corneal crystals, become more evident. With our experience with 172 patients followed up at the National Institutes of Health between 1976 and 2000, the prevalence of anterior segment complications in nephropathic cystinosis was determined.
METHODS: A cross-sectional examination of age-specific prevalence was performed with logistic regression analysis of prevalence change with age.
RESULTS: Besides the corneal crystals apparent in all age groups, superficial punctate keratopathy, filamentary keratopathy, severe peripheral corneal neovascularization, band keratopathy, and posterior synechiae with iris thickening and transillumination were noted in the older age groups. The prevalence increased with age for each complication.
CONCLUSIONS: As patients with cystinosis grow older, more severe ophthalmic manifestations become evident. It remains to be seen how the prevalence of these complications will be altered by early initiation of oral and topical cysteamine therapy.

Entities:  

Mesh:

Year:  2002        PMID: 11862089     DOI: 10.1097/00003226-200203000-00009

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  17 in total

1.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

Review 2.  Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature.

Authors:  Ekaterini Tsilou; Min Zhou; William Gahl; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 6.048

3.  Cystinosis as a lysosomal storage disease with multiple mutant alleles: Phenotypic-genotypic correlations.

Authors:  Mohammad Al-Haggar
Journal:  World J Nephrol       Date:  2013-11-06

Review 4.  Potential use of stem cells as a therapy for cystinosis.

Authors:  Celine J Rocca; Stephanie Cherqui
Journal:  Pediatr Nephrol       Date:  2018-05-22       Impact factor: 3.714

Review 5.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

6.  Treatment of Inherited Eye Defects by Systemic Hematopoietic Stem Cell Transplantation.

Authors:  Celine J Rocca; Alexander Kreymerman; Sarah N Ur; Katie E Frizzi; Swati Naphade; Athena Lau; Tammy Tran; Nigel A Calcutt; Jeffrey L Goldberg; Stephanie Cherqui
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 7.  Adult complications of nephropathic cystinosis: a systematic review.

Authors:  Rachel Nora Kasimer; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2020-02-03       Impact factor: 3.714

Review 8.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

Review 9.  Cystinosis: practical tools for diagnosis and treatment.

Authors:  Martijn J Wilmer; Joost P Schoeber; Lambertus P van den Heuvel; Elena N Levtchenko
Journal:  Pediatr Nephrol       Date:  2010-08-24       Impact factor: 3.714

10.  Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouse.

Authors:  Jennifer Simpson; Chyong Jy Nien; Kevin Flynn; Brian Jester; Stephanie Cherqui; James Jester
Journal:  Mol Vis       Date:  2011-08-17       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.